Provided by Tiger Trade Technology Pte. Ltd.

AMPLIFY WEIGHT LOSS DRUG & TREATMENT ETF

24.56
-0.1349-0.55%
Post-market: 24.55-0.0094-0.04%16:10 EDT
Volume:2K
Turnover:51.59K
Market Cap:5.65M
PE:- -
High:24.72
Open:24.72
Low:24.47
Close:24.69
52wk High:27.94
52wk Low:22.89
Shares:230.00K
Float Shares:230.00K
Volume Ratio:7.12
T/O Rate:0.91%
Dividend:0.41
Dividend Rate:1.68%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Sep 25

Eli Lilly and Co Stock (LLY) Moved Up by 3.73% on Sep 24: A Full Analysis

TradingKey
·
Sep 24

Lilly's Next-Gen Obesity Efforts Could Tip Scales Further in Its Favor, Citi Says

Reuters
·
Sep 24

Viking Therapeutics Shares Down 15% After Co Prices Upsized Stock, Convertible Offerings

THOMSON REUTERS
·
Sep 24

U.S. Stocks on the MOVE-Everpure, Dropbox, Darden Restaurants

Reuters
·
Sep 24

Truist Lifts Price Target on Scholar Rock Holding to $77 From $76, Keeps Buy Rating

MT Newswires Live
·
Sep 24

Viking Therapeutics, - Offering Size Increased to $275 Mln Common Stock and $225 Mln Notes

THOMSON REUTERS
·
Sep 24

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Dow Jones
·
Sep 24

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

THOMSON REUTERS
·
Sep 24

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

Novo Nordisk's new strategy hinges on something it cannot manufacture: investor confidence

Deep News
·
Sep 24

Viking Therapeutics Shares Down 8.7% Premarket After Co Announces Planned Stock, Convertible Offerings

THOMSON REUTERS
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24

Viking Therapeutics $200M Spot Secondary; price range $35.00-$38.00

TIPRANKS
·
Sep 24

Viking Therapeutics Slips on Planned Stock, Convertible Offerings

Reuters
·
Sep 24

Viking Therapeutics Plans USD 200 Million Convertible Senior Notes Offering Due 2032

Reuters
·
Sep 24

Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes

THOMSON REUTERS
·
Sep 24

Viking Therapeutics, - to Offer $200 Mln Common Stock and $200 Mln Convertible Notes Due 2032

THOMSON REUTERS
·
Sep 24

Viking Therapeutics, - Proceeds to Fund Vk2735, Vk3019 Clinical Development and General Corporate Purposes

THOMSON REUTERS
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24